Liver Cirrhosis as a Risk Factor for Direct-Acting Antiviral Therapy Failure in Real-Life Hepatitis C Virus/Human Immunodeficiency Virus Coinfection. (27th July 2017)

• Record Type: Journal Article
• Authors: Boesecke, Christoph; Ingiliz, Patrick; Berger, Florian; Lutz, Thomas; Schewe, Knud; Schulze zur Wiesch, Julian; Baumgarten, Axel; Christensen, Stefan; Rockstroh, Jürgen K; Mauss, Stefan
• Is Part Of: Open forum infectious diseases. Volume 4:Number 3(2017)
• Publication Date: 2017-07-27
• Subjects: chronic hepatitis C -- DAA -- HCV/HIV coinfection -- HCV treatment; Communicable diseases -- Periodicals; Medical microbiology -- Periodicals; Infection -- Periodicals; 616.9
• DOI: 10.1093/ofid/ofx158
• Languages: English
• ISSNs: 2328-8957

Abstract

Abstract: Current hepatitis C virus (HCV) treatment guidelines recommend treating HCV/human immunodeficiency virus (HIV)-coinfected individuals similar to HCV-monoinfected individuals. Recently inferior response rates to direct acting antiviral (DAA) therapy in HCV/HIV coinfection have been reported. Our German hepatitis C cohort (GECCO) cohort data show that coinfected patients with liver cirrhosis are less likely to achieve viral eradication.